59.55
price down icon0.10%   -0.06
after-market After Hours: 59.55
loading
Incyte Corp stock is traded at $59.55, with a volume of 1.87M. It is down -0.10% in the last 24 hours and down -1.23% over the past month. Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$59.61
Open:
$59.95
24h Volume:
1.87M
Relative Volume:
0.94
Market Cap:
$12.13B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
425.36
EPS:
0.14
Net Cash Flow:
$16.80M
1W Performance:
-4.96%
1M Performance:
-1.23%
6M Performance:
-27.68%
1Y Performance:
+9.53%
1-Day Range:
Value
$59.07
$60.07
1-Week Range:
Value
$59.07
$62.87
52-Week Range:
Value
$52.81
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
Name
Incyte Corp
Name
Phone
(302) 498-6700
Name
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Employee
2,617
Name
Twitter
@Incyte
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
INCY's Discussions on Twitter

Compare INCY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INCY
Incyte Corp
59.55 12.13B 4.08B 32.48M 16.80M 0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.82 130.98B 11.10B -988.90M -978.00M -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 64.65B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
622.93 39.39B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.55 34.32B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
232.25 28.03B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-18-25 Downgrade Guggenheim Buy → Neutral
Mar-18-25 Downgrade William Blair Outperform → Mkt Perform
Dec-17-24 Initiated UBS Neutral
Oct-29-24 Upgrade BofA Securities Neutral → Buy
Oct-01-24 Initiated Wolfe Research Outperform
Sep-18-24 Downgrade Truist Buy → Hold
Jul-02-24 Downgrade BMO Capital Markets Market Perform → Underperform
May-23-24 Initiated Deutsche Bank Hold
Apr-23-24 Initiated Cantor Fitzgerald Neutral
Feb-23-24 Initiated Jefferies Buy
Feb-14-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-13-23 Upgrade Leerink Partners Market Perform → Outperform
Dec-04-23 Upgrade Guggenheim Neutral → Buy
Nov-21-23 Downgrade Goldman Buy → Neutral
Jul-25-23 Initiated Citigroup Buy
May-04-23 Downgrade BofA Securities Buy → Neutral
Apr-10-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-24-23 Upgrade SVB Securities Underperform → Market Perform
Jan-31-23 Initiated Piper Sandler Overweight
Aug-03-22 Downgrade Evercore ISI Outperform → In-line
Aug-03-22 Downgrade Guggenheim Buy → Neutral
Jul-28-22 Initiated Wells Fargo Equal Weight
Feb-09-22 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-18-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-19-21 Initiated BMO Capital Markets Market Perform
Jul-20-21 Upgrade The Benchmark Company Hold → Buy
Feb-10-21 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-07-21 Initiated Truist Buy
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Jun-16-20 Initiated The Benchmark Company Hold
May-06-20 Downgrade JP Morgan Overweight → Neutral
Apr-29-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-24-20 Resumed William Blair Outperform
Mar-13-20 Upgrade BofA/Merrill Neutral → Buy
Feb-04-20 Resumed BofA/Merrill Neutral
Jan-03-20 Reiterated BMO Capital Markets Market Perform
Jan-03-20 Downgrade Mizuho Buy → Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Oct-03-19 Initiated Mizuho Buy
Sep-12-19 Initiated BMO Capital Markets Market Perform
Sep-05-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Sep-05-19 Resumed Morgan Stanley Equal-Weight
Sep-05-19 Upgrade Oppenheimer Perform → Outperform
May-21-19 Initiated Credit Suisse Neutral
May-03-19 Downgrade Barclays Overweight → Equal Weight
Apr-11-19 Initiated Stifel Hold
Apr-03-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-24-19 Upgrade William Blair Mkt Perform → Outperform
View All

Incyte Corp Stock (INCY) Latest News

pulisher
May 07, 2025

Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360

May 07, 2025
pulisher
May 07, 2025

US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex

May 07, 2025
pulisher
May 07, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

May 07, 2025
pulisher
May 07, 2025

Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News

May 07, 2025
pulisher
May 07, 2025

Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.

May 07, 2025
pulisher
May 07, 2025

Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress - MyChesCo

May 07, 2025
pulisher
May 05, 2025

Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com

May 05, 2025
pulisher
May 05, 2025

Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360

May 05, 2025
pulisher
May 02, 2025

Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN

May 02, 2025
pulisher
May 01, 2025

Polycythemia vera Market: Epidemiology, Therapies, - openPR.com

May 01, 2025
pulisher
May 01, 2025

Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com

May 01, 2025
pulisher
May 01, 2025

Incyte to Present at Upcoming Investor Conference - Business Wire

May 01, 2025
pulisher
May 01, 2025

Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

9 Analysts Have This To Say About IncyteIncyte (NASDAQ:INCY) - Benzinga

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

BofA Boosts Incyte (INCY) Price Target Following Q1 Results | IN - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte (INCY) Target Price Raised by Wells Fargo Despite Mixed R - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, Medac GmbH, AltruBio Inc., Incyte Corporation - Barchart.com

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte: Q1 Earnings Snapshot - CT Insider

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Reve - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MSN

Apr 30, 2025
pulisher
Apr 29, 2025

Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

BofA raises Incyte stock price target to $89, maintains Buy rating - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 29, 2025

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Corp Raises Jakafi Sales Forecast Following Strong Performance - Finimize

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key P - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Q1 2025 slides: 26% product revenue growth, Jakafi guidance raised - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs | INCY Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Q1 Results Top Estimates - Nasdaq

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key Products | INCY Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte earnings beat by $0.12, revenue topped estimates - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Reports 2025 First Quarter Financial Results - TradingView

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte (INCY) Set to Announce Q1 Earnings, Analysts Cautious - GuruFocus

Apr 29, 2025
pulisher
Apr 28, 2025

Incyte (INCY) Q1 Earnings Report Preview: What To Look For - Barchart.com

Apr 28, 2025
pulisher
Apr 25, 2025

Incyte to Highlight Early-Stage Oncology Data at American Associ - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire

Apr 25, 2025
pulisher
Apr 24, 2025

4Q24 earnings stir biopharma stocks, leading to mixed performance - BioWorld MedTech

Apr 24, 2025
pulisher
Apr 24, 2025

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - BioSpace

Apr 24, 2025

Incyte Corp Stock (INCY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$68.28
price up icon 0.60%
$20.60
price up icon 0.88%
$32.75
price up icon 1.99%
$24.29
price up icon 0.37%
$92.80
price down icon 2.05%
biotechnology ONC
$232.25
price down icon 3.93%
Cap:     |  Volume (24h):